Form 4: Moderna Director Stephen Berenson Reports Stock Transactions

Director Stephen Berenson reported the vesting of restricted stock units and acquisition of stock options in Moderna, Inc.

Summary

• On May 3, 2024, Stephen Berenson, a director of Moderna, Inc., reported transactions involving the company's stock.
• Berenson acquired 732 shares of common stock upon the vesting of restricted stock units.
• These restricted stock units convert into common stock on a one-for-one basis and vested fully on May 3, 2024.
• Following the transaction, Berenson directly owns 22,203 shares of Moderna common stock.
• On May 6, 2024, Berenson acquired 7,557 stock options with an exercise price of $122.13.
• These options will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to continued service.
• Berenson directly owns 7,557 stock options.

Sentiment

Score: 5

Explanation: This is a routine disclosure of insider transactions, neither particularly positive nor negative. It reflects standard compensation practices.

Positives

• The vesting of restricted stock units and acquisition of stock options could be seen as a positive sign of the director's confidence in the company's future.

Future Outlook

The stock options will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of shares outstanding upon exercise of the options.

Key Dates